CC
BCLI

Clearline Capital’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Clearline Capital’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-3,546
Closed -$208K – 42
2017
Q4 		$208K Buy
+3,546
New +$212K 0.11% 46

Other funds holding BCLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PVH
Psagot Value Holdings Tel Aviv, Israel $11M AUM 32.09% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Clearline Capital's BCLI Position: Q1 2018 in Review

Clearline Capital sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q1 2018, closing a stake of 3,546 shares — an estimated $208K sold.

Clearline Capital first reported a position in BCLI in Q4 2017 and held it in 1 quarter. The position peaked at $208K in Q4 2017. 34 funds tracked by Wall St. Rank hold BCLI as of Q1 2018.

  • Clearline Capital reported no remaining BRAINSTORM CELL THERAPUTC position as of Q1 2018 after selling out during the quarter.
  • Clearline Capital sold 3,546 BRAINSTORM CELL THERAPUTC shares in Q1 2018, an estimated $208K.
  • Clearline Capital first reported a position in BRAINSTORM CELL THERAPUTC in Q4 2017 and held it in 1 quarter.
  • Clearline Capital's BRAINSTORM CELL THERAPUTC position peaked at $208K in Q4 2017.
  • 34 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q1 2018.

Based on Clearline Capital's 13F filing for Q1 2018, filed 15 May 2018.